28053186|t|AAV9 - NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease
28053186|a|Niemann-Pick type C (NPC) disease is a fatal inherited neurodegenerative disorder caused by loss-of-function mutations in the NPC1 or NPC2 gene. There is no effective way to treat NPC disease. In this study, we used adeno-associated virus (AAV) serotype 9 (AAV9) to deliver a functional NPC1 gene systemically into NPC1(-/-) mice at postnatal day 4. One single AAV9-NPC1 injection resulted in robust NPC1 expression in various tissues, including brain, heart, and lung. Strikingly, AAV9-mediated NPC1 delivery significantly promoted Purkinje cell survival, restored locomotor activity and coordination, and increased the lifespan of NPC1(-/-) mice. Our work suggests that AAV-based gene therapy is a promising means to treat NPC disease.
28053186	0	4	AAV9	T005	C1564874
28053186	7	11	NPC1	T028	C1417776
28053186	12	25	significantly	T078	C0750502
28053186	26	37	ameliorates	T033	C0243095
28053186	38	51	Purkinje cell	T025	C0034143
28053186	52	57	death	T043	C0007587
28053186	62	86	behavioral abnormalities	T048	C0233514
28053186	90	95	mouse	T015	C0025929
28053186	96	107	NPC disease	T047	C0220756
28053186	108	141	Niemann-Pick type C (NPC) disease	T047	C0220756
28053186	147	152	fatal	T080	C1302234
28053186	153	162	inherited	T169	C0439660
28053186	163	189	neurodegenerative disorder	T047	C0524851
28053186	200	216	loss-of-function	T033	C0243095
28053186	217	226	mutations	T045	C0026882
28053186	234	238	NPC1	T028	C1417776
28053186	242	251	NPC2 gene	T028	C1422736
28053186	282	287	treat	T169	C1292734
28053186	288	299	NPC disease	T047	C0220756
28053186	324	346	adeno-associated virus	T005	C1564874
28053186	348	351	AAV	T005	C1564874
28053186	353	363	serotype 9	T170	C0449943
28053186	365	369	AAV9	T005	C1564874
28053186	384	394	functional	T169	C0205245
28053186	395	404	NPC1 gene	T028	C1417776
28053186	405	417	systemically	T169	C0205373
28053186	423	432	NPC1(-/-)	T028	C1417776
28053186	433	437	mice	T015	C0206745
28053186	441	456	postnatal day 4	T061	C0419611
28053186	462	468	single	T081	C0205171
28053186	469	488	AAV9-NPC1 injection	T061	C0021485
28053186	501	507	robust	T080	C2986815
28053186	508	512	NPC1	T028	C1417776
28053186	513	523	expression	T045	C0017262
28053186	535	542	tissues	T024	C0040300
28053186	554	559	brain	T023	C0006104
28053186	561	566	heart	T023	C0018787
28053186	572	576	lung	T023	C0024109
28053186	590	603	AAV9-mediated	T054	C0086597
28053186	604	617	NPC1 delivery	T077	C1524066
28053186	618	631	significantly	T078	C0750502
28053186	632	640	promoted	T052	C0033414
28053186	641	654	Purkinje cell	T025	C0034143
28053186	655	663	survival	T052	C0038952
28053186	674	692	locomotor activity	T040	C0023946
28053186	697	709	coordination	T042	C0237543
28053186	715	724	increased	T081	C0205217
28053186	729	737	lifespan	T079	C1254367
28053186	741	750	NPC1(-/-)	T028	C1417776
28053186	751	755	mice	T015	C0206745
28053186	780	802	AAV-based gene therapy	T061	C0860404
28053186	827	832	treat	T169	C1292734
28053186	833	844	NPC disease	T047	C0220756